Amylyx Pharmaceuticals (AMLX) Cash Flow: Operating & Free Cash Flow

Amylyx Pharmaceuticals Cash Flow Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for Amylyx Pharmaceuticals, Inc. (AMLX) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Operating Activities
Net Income	-301.74	-301.74	49.27	-198.38	-87.93	-42.28	-13.72
Depreciation & Amortization	0.53	0.90	1.09	0.49	0.05	0.00	0.00
Stock Based Compensation	27.65	33.04	37.16	21.71	3.14	0.24	0.00
Change in Working Capital	-1.08	-45.83	-65.66	-1.64	4.60	2.60	3.50
Change in Accounts Receivable	0.36	39.60	-74.74	-15.31	-0.14	0.00	0.00
Change in Inventory	5.96	-9.25	-73.13	-9.77	0.00	0.00	0.00
Change in Accounts Payable	0.58	-19.10	15.88	1.85	0.67	1.42	1.28
Change in Other Working Capital	0.91	-57.08	-5.27	-4.47	-4.51	1.18	2.22
Other Operating Activities	-5.70	145.99	-9.94	-2.06	5.35	2.74	-0.48
Net Cash from Operating Activities	-123.34	-167.65	11.92	-179.87	-74.80	-36.70	-10.69
Investing Activities
Capital Expenditures	-0.14	-0.16	-1.24	-2.53	-0.35	-0.15	0.00
Acquisitions	0.00	0.00	0.00	236.46	0.00	0.00	0.00
Purchases of Investments	-231.82	-231.99	-300.83	-415.87	-49.05	0.00	0.00
Sales/Maturities of Investments	246.00	344.00	394.12	179.41	3.00	0.00	0.00
Other Investing Activities	0.00	-36.20	0.00	-236.46	0.00	0.00	0.00
Net Cash from Investing Activities	14.04	75.65	92.05	-238.99	-46.41	-0.15	0.00
Financing Activities
Debt Repayment	0.00	0.00	0.00	0.00	25.90	16.82	0.64
Common Stock Issued	4.08	2.13	6.99	434.64	0.34	0.05	0.03
Common Stock Repurchased	0.00	0.00	-3.32	0.00	0.00	0.00	0.00
Other Financing Activities	252.95	-1.78	-3.45	-2.85	-2.73	30.01	0.00
Net Cash from Financing Activities	257.03	0.35	3.54	431.79	158.51	46.82	0.67
Summary
Effect of Forex Changes on Cash	1.07	-0.44	0.16	-0.07	0.01	0.00	13.11
Net Change in Cash	148.80	-92.08	107.68	12.87	37.31	9.98	3.09
Cash at Beginning of Period	78.84	170.92	63.25	50.38	13.07	3.09	0.00
Cash at End of Period	227.64	78.84	170.92	63.25	50.38	13.07	3.09
Free Cash Flow	-123.48	-167.80	10.68	-182.40	-75.15	-36.85	-10.69
Supplemental Disclosures
Income Taxes Paid	-	0.71	6.39	0.03	-	-	-

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Amylyx Pharmaceuticals Cash Flow

What is Amylyx Pharmaceuticals's free cash flow?

Amylyx Pharmaceuticals had negative free cash flow of $123.48M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$123.34M minus $138.00K of capital expenditures.

How much does Amylyx Pharmaceuticals spend on capital expenditures?

Amylyx Pharmaceuticals spent $138.00K on capital expenditures in fiscal 2025, compared with $157.00K a year earlier.

Does Amylyx Pharmaceuticals pay dividends or buy back shares?

Amylyx Pharmaceuticals's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition